3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
9
Melanoma
4
Ganglioneuroblastoma
4
Triple Negative Breast Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Transplant-Related Hematologic Malignancy
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Cisplatin
4
Carboplatin
4
Biopsy
4
trastuzumab deruxtecan
3
Trastuzumab
3
Platinum
3
Goserelin
3
Docetaxel
3
sacituzumab govitecan
2
pertuzumab
2
entrectinib
2
darolutamide
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
spartalizumab
1
selinexor
1
pyrotinib
1
luprolide acetate gel depot
1
lenvatinib
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
sargramostim
×
1 year
×
Clear all
No trials found.